Antabio SAS advances cystic fibrosis programme Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients more ➔
Hydrogel fights wound infection and inflammation Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds. more ➔
British diagnostics play OBD lands contract with US pharmaThe technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic … more ➔
Truffle’s BioMedTech fund filled with €250mParis-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach. more ➔
Cellestia: €20m to get to Phase IIBasel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million. more ➔
Biomarker identifies residual congestion in heart failure patientsData from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients. more ➔
Belgian start-up takes fight on neuropathiesThe new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with €4.2m from mainly local investors, … more ➔
Second clinical failure of Transgene in 2019French Transgene SA said it has terminated its lead programme TG4010 in combination with chemotherapy and checkpoint inhibition. more ➔
Microbiota contribute to skin damage in cancer therapy New research demonstrates that disruption of EGF receptor signalling allows commensal bacteria to invade hairs and cause skin lesions. more ➔
BIOncoTech Therapeutics and MSD combine cancer drugsMadrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary. more ➔
